ESMO Highlights: Breast cancer
ESMO Highlights: Breast cancer
Cancer care in developing countries
Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma
Nivolumab potentially superior to standard chemo in advanced melanoma
Targeted therapy for iodine-refractory thyroid cancer
Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma
Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib
Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma
Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer
Cediranib and chemo combo improves PFS for metastatic cervical cancer